XBIT XBiotech: רווח למניה לשנה מתגלגלת

XBiotech Inc. (XBIT) develops human antibodies to combat tumors, protecting its innovations with patent barriers. The therapy's effectiveness relies on strict medical oversight during the transport of drugs to clinics. Serving as the primary valuation tool, this chart on GURU.Markets reflects an EPS of -49.30. The company is currently scaling its portfolio of immune solutions in an effort to attract major strategic allies.

For XBiotech Inc. (XBIT), the dependence on the success of a narrow portfolio of oncology antibodies makes the 12-month EPS growth rate a critical indicator of financial stability. This metric measures the percentage change in net income per share over a trailing twelve-month (TTM) period, allowing investors to promptly assess the impact of patent risks and operational shocks on the actual return on equity.